High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Projektinformationen

TUMOURPRINT

ID Finanzhilfevereinbarung: 829846

DOI

10.3030/829846

Projekt abgeschlossen

EK-Unterschriftsdatum 29 Oktober 2018

Startdatum 1 September 2018

Enddatum 31 Januar 2021

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 3 500 467,50

EU-Beitrag

€ 2 450 327,25

Koordiniert durch

BICO GROUP AB
Sweden

Periodic Reporting for period 3 - TUMOURPRINT (High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research)

Berichtszeitraum: 2020-09-01 bis 2021-01-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development). The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

In the first reporting period significant progress has been achieved regarding the hardware and software components of the platform. The progress achieved allows the team to intensify development and validation activities envisaged for the second reporting period.
In PR2 the project is proceeding according to the time plan and in line with our expectations. The major deliverables and milestones have been submitted to the EU. In the PR2 we have achieved Milestone 2, Milestone 3 and Milestone 5.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-topay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way. CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cellspecific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

Company logo